Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Autoimmune thyroiditis
Graves’ disease
Graves’ ophthalmopathy
Graves’ orbitopathy
Insulin-like growth factor-1 receptor
Thyroid
Thyroid autoimmunity
Thyroid eye disease
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
26
07
2018
accepted:
09
08
2018
pubmed:
23
8
2018
medline:
28
7
2019
entrez:
23
8
2018
Statut:
ppublish
Résumé
A role of the insulin-like growth factor-1 receptor (IGF-1R) in the pathogenesis of Graves' orbitopathy (GO) has been proposed, but the existence and function of anti-IGF-1R-antibodies (IGF-1R-Abs) are debated. We designed a cross-sectional investigation to measure serum IGF-1R-Abs by a commercial assay in consecutive patients with Graves' disease (GD) compared with healthy subjects and patients with autoimmune thyroiditis (AT). A total of 134 subjects were screened including 27 healthy subjects, 80 GD patients (54 of whom with GO), and 27 AT patients. The main outcome measure was the prevalence of positive serum IGF-1R-Abs in GO, compared with GD without GO and with the other study groups. Having established a cut-off value at 55.2 ng/ml for positive tests, positive IGF-1R-Abs were more frequent in GD (25%), than in AT (3.7%, P = 0.003) and healthy subjects (0%, P = 0.006). Within GD, there was no difference between patients with or without GO. Serum levels of IGF-1R-Abs differed across the study population (P < 0.0001), reflecting their higher concentrations in GD (P < 0.0001 vs both AT and healthy subjects), but with no difference between patients with or without GO. In patients with GO, there was an inverse correlation between serum IGF-1R-Abs and CAS (R = - 0.376, 95% CI: from - 0.373 to - 0.631; P = 0.005), the significance of which remains to be investigated. Serum autoantibodies against the IFG-1R are present in one-fourth of GD patients, regardless of the presence of GO. Further functional studies are needed to investigate the significance of their inverse correlation with GO activity.
Sections du résumé
BACKGROUND
BACKGROUND
A role of the insulin-like growth factor-1 receptor (IGF-1R) in the pathogenesis of Graves' orbitopathy (GO) has been proposed, but the existence and function of anti-IGF-1R-antibodies (IGF-1R-Abs) are debated.
METHODS
METHODS
We designed a cross-sectional investigation to measure serum IGF-1R-Abs by a commercial assay in consecutive patients with Graves' disease (GD) compared with healthy subjects and patients with autoimmune thyroiditis (AT). A total of 134 subjects were screened including 27 healthy subjects, 80 GD patients (54 of whom with GO), and 27 AT patients. The main outcome measure was the prevalence of positive serum IGF-1R-Abs in GO, compared with GD without GO and with the other study groups.
RESULTS
RESULTS
Having established a cut-off value at 55.2 ng/ml for positive tests, positive IGF-1R-Abs were more frequent in GD (25%), than in AT (3.7%, P = 0.003) and healthy subjects (0%, P = 0.006). Within GD, there was no difference between patients with or without GO. Serum levels of IGF-1R-Abs differed across the study population (P < 0.0001), reflecting their higher concentrations in GD (P < 0.0001 vs both AT and healthy subjects), but with no difference between patients with or without GO. In patients with GO, there was an inverse correlation between serum IGF-1R-Abs and CAS (R = - 0.376, 95% CI: from - 0.373 to - 0.631; P = 0.005), the significance of which remains to be investigated.
CONCLUSIONS
CONCLUSIONS
Serum autoantibodies against the IFG-1R are present in one-fourth of GD patients, regardless of the presence of GO. Further functional studies are needed to investigate the significance of their inverse correlation with GO activity.
Identifiants
pubmed: 30132285
doi: 10.1007/s40618-018-0943-8
pii: 10.1007/s40618-018-0943-8
doi:
Substances chimiques
Autoantibodies
0
Biomarkers
0
IGF1R protein, human
0
Receptors, Somatomedin
0
Receptor, IGF Type 1
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Pagination
471-480Subventions
Organisme : Università di Pisa
ID : Fondi di Ateneo
Références
J Immunol. 2002 Jan 15;168(2):942-50
pubmed: 11777993
J Immunol. 2003 Jun 15;170(12):6348-54
pubmed: 12794168
Orbit. 2004 Sep;23(3):161-8
pubmed: 15545129
J Clin Endocrinol Metab. 2006 Sep;91(9):3464-70
pubmed: 16835285
Thyroid. 2007 Jun;17(6):525-8
pubmed: 17614772
Eur J Ophthalmol. 2008 Mar-Apr;18(2):165-71
pubmed: 18320506
J Immunol. 2008 Sep 15;181(6):4397-405
pubmed: 18768899
Thyroid. 2008 Sep;18(9):983-8
pubmed: 18788919
Optom Vis Sci. 2008 Oct;85(10):1012-7
pubmed: 18832980
Clin Exp Ophthalmol. 2009 Jul;37(5):496-502
pubmed: 19624347
J Clin Endocrinol Metab. 2011 Aug;96(8):2386-94
pubmed: 21677036
J Clin Endocrinol Metab. 2012 Jan;97(1):E44-8
pubmed: 22031515
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):291-302
pubmed: 22632366
Thyroid. 2013 Jan;23(1):97-102
pubmed: 23088654
J Clin Endocrinol Metab. 2013 Feb;98(2):752-60
pubmed: 23264397
J Clin Endocrinol Metab. 2013 Feb;98(2):769-76
pubmed: 23295466
J Endocrinol Invest. 2013 Jun;36(6):444-9
pubmed: 23587873
Thyroid. 2015 Mar;25(3):347-51
pubmed: 25584927
J Endocrinol Invest. 2015 Jun;38(6):661-8
pubmed: 25596664
J Endocrinol Invest. 2015 Aug;38(8):809-15
pubmed: 25740065
Horm Metab Res. 2015 Sep;47(10):773-8
pubmed: 26361262
J Clin Endocrinol Metab. 2016 Jun;101(6):2340-7
pubmed: 27043163
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
J Endocrinol Invest. 2017 May;40(5):547-553
pubmed: 28176220
Thyroid. 2017 May;27(5):746-747
pubmed: 28346855
Orphanet J Rare Dis. 2017 Apr 20;12(1):72
pubmed: 28427469
N Engl J Med. 2017 May 4;376(18):1748-1761
pubmed: 28467880
J Endocrinol Invest. 2017 Aug;40(8):885-887
pubmed: 28634704
Thyroid. 2017 Nov;27(11):1458-1459
pubmed: 28847224
Thyroid. 2017 Nov;27(11):1459-1460
pubmed: 28922977
J Mol Endocrinol. 2018 Jul;61(1):T29-T43
pubmed: 29273685
Thyroid. 2018 Mar;28(3):386-394
pubmed: 29336220
Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298
pubmed: 29396246
J Endocrinol Invest. 2018 Sep;41(9):1037-1042
pubmed: 29450866
Thyroid. 2018 May;28(5):650-655
pubmed: 29631510
JAMA Ophthalmol. 2018 Jun 1;136(6):613-619
pubmed: 29710102
Autoimmunity. 1993;16(4):251-7
pubmed: 7517705